KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study. PMID 41800821 · Pharmacotherapy · 2026-Apr The trial is not eligible because the phase is not established as Phase III/IIIb or Phase II/III, and the primary endpoint is a neurotoxicity endpoint, not a malignancy efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
BEAT-BK: An Adaptive, Randomized Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney-pancreas Transplantation Recipients (BEAT-BK) Study Protocol. PMID 41799026 · Transplant Direct · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A pre-operative two-week very low-calorie diet to reduce steatosis before liver resection (RESOLVE): A multi-centre randomised controlled feasibility trial. PMID 41797062 · Eur J Surg Oncol · 2026-Apr The study is a feasibility trial evaluating a very low-calorie diet (non-drug intervention) before liver resection for liver neoplasms. It is not a Phase III or definitive randomized trial, and no time-to-event efficacy endpoints (e.g., OS, PFS) or Kaplan-Meier analyses are reported. The intervention is not drug-containing.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risk factors for recurrence of vulvar high-grade squamous intra-epithelial lesions: long-term follow-up of the PITVIN Study (primary imiquimod vs surgery for vulvar intra-epithelial neoplasia). PMID 41791272 · Int J Gynecol Cancer · 2026-Apr The record describes a long-term follow-up of a Phase 3 randomized trial of imiquimod vs surgery for vulvar HSIL. While it meets criteria for oncology, human, randomized, Phase 3, and drug intervention, the efficacy endpoint is recurrence of a pre-cancerous lesion (HSIL), not a time-to-event endpoint for a malignant neoplasm (e.g., OS, PFS, DFS). Therefore, it does not meet the required primary/key secondary time-to-event efficacy endpoint for a human malignant neoplasm. The report is also a secondary analysis (long-term follow-up) rather than a primary efficacy report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine. PMID 41781546 · Nat Med · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Likelihood ratio test for the disease progression model to measure saved time in Alzheimer's disease. PMID 41773781 · Stat Methods Med Res · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Suzetrigine for Acute Pain in the Emergency Department: A First-in-Class NaV1.8 Blocker. PMID 41767204 · J Am Coll Emerg Physicians Open · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial). PMID 41763966 · Ann Rheum Dis · 2026-Apr The study is a randomized Phase III trial of a drug (ozoralizumab, a TNF inhibitor) in rheumatoid arthritis, not a human malignant neoplasm. While it meets criteria for randomized, phase 3, human, drug intervention, and original result, it is excluded because it is non-oncology and the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, etc.).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial. PMID 41763237 · Lancet Respir Med · 2026-Apr Study is a Phase III randomized trial in oncology with human participants and an original primary result, but it does not meet the core eligibility criteria because it lacks a primary/key time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) and its intervention is a medical device (IPC) combined with a procedure, not a drug-containing intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of etifoxine versus alprazolam in generalized anxiety disorders with somatic symptoms: A randomized, double-blind, comparative study. PMID 41763071 · J Anxiety Disord · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Renal Flares and Health-Related Quality of Life Among Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from the LUNAR Phase 3 Clinical Trial. PMID 41761038 · Rheumatol Ther · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical efficacy of Xiaotan Sanjie decoction in treating gastric cancer with peritoneal metastases: A study protocol for a randomized controlled trial. PMID 41756199 · Contemp Clin Trials Commun · 2026-Apr 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. PMID 41735092 · J Clin Lipidol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer. PMID 41731117 · Br J Cancer · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. PMID 41730814 · Lancet Diabetes Endocrinol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy. PMID 41730506 · Diabetes Res Clin Pract · 2026-Apr The record describes a pharmacogenetic substudy of the FIELD trial. While the FIELD trial itself is a Phase III randomized trial of a drug (fenofibrate) with time-to-event efficacy endpoints, the specific study is not an oncology trial. Its primary outcomes are diabetic vascular complications and mortality; cancer-related mortality is only one of several secondary mortality endpoints analyzed in the context of a genetic variant. Therefore, it does not meet the core requirement of being a report on an oncology (human malignant neoplasm) clinical trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The differential effects of social support on quality of life in head and neck cancer patients in the United States and China. PMID 41723882 · Eur J Oncol Nurs · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT. PMID 41717679 · Hypertension · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma. PMID 41714403 · Leukemia · 2026-Apr The record describes a translational/biomarker study (miR-29 in follicular lymphoma) that uses a published RCT (SWOG S0016) as a validation cohort for survival correlations. It is not a report of the original, formal, drug-containing, Phase III/IIIb or Phase II/III randomized trial's efficacy results. The drug intervention criterion is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of polymer oxygenated alginate dressings for healing skin graft donor areas: A phase III randomized controlled trial. PMID 41713054 · Burns · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Classic Hodgkin Lymphoma in the Older Adult: What's New? PMID 41708412 · Hematol Oncol Clin North Am · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical protocol for the K-3 trial: a single-center, patient-blinded, randomized clinical trial addressing anesthesiologic, oncological and patient recovery outcomes of standard flank approach vs supine approach for robot-assisted partial nephrectomy. PMID 41707608 · Surg Oncol · 2026-Apr 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Machine Learning to Predict Outcomes and Dosing Frequency With Aflibercept for Macular Edema Following Central Retinal Vein Occlusion. PMID 41705990 · Ophthalmic Surg Lasers Imaging Retina · 2026-Apr 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma. PMID 41704058 · Br J Haematol · 2026-Apr The record describes a randomized, multicentre trial with a primary EFS endpoint and formal results, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. Phase classification cannot be established from the abstract alone.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial. PMID 41702154 · Oral Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. PMID 41692019 · Lancet Respir Med · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial. PMID 41691937 · Neuromuscul Disord · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial. PMID 41690405 · Radiother Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes. PMID 41689888 · J Prev Alzheimers Dis · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial. PMID 41689868 · Urol Oncol · 2026-Apr The record is a randomized, oncology trial with drug intervention and key time-to-event endpoints (RFS, PFS) reported via Kaplan-Meier. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided information, which is a required criterion for eligibility. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY. PMID 41679125 · J Diabetes Complications · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ASO Visual Abstract: Health Care Utilization, Costs, and Cost-Effectiveness for Patients Undergoing Laparoscopic and Open Hemihepatectomy: A Secondary Analysis of the ORANGE II PLUS Randomised Controlled, Phase 3, Superiority Trial. PMID 41670859 · Ann Surg Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy. PMID 41670693 · Naunyn Schmiedebergs Arch Pharmacol · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial. PMID 41667130 · BJU Int · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins. PMID 41664920 · Circ Genom Precis Med · 2026-Apr 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial. PMID 41662856 · Lancet Gastroenterol Hepatol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata. PMID 41645877 · J Dermatol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America: Results From the EMPOwER Study. PMID 41641373 · Neurol Clin Pract · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Association between treatment-induced changes in the Kansas City Cardiomyopathy Questionnaire and clinical outcomes in chronic heart failure: a trial-level meta-regression analysis. PMID 41641158 · Int J Cardiol Heart Vasc · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index. PMID 41637791 · Breast · 2026-Apr This is a secondary analysis (prognostic biomarker validation) of two Phase III randomized trials (SOFT/TEXT). While it meets criteria for oncology, human, randomized, time-to-event, and drug intervention, it does not represent a primary report of the trial's efficacy results for a drug-containing intervention. The abstract describes a reclassification of risk groups using a biomarker index, not the primary trial comparison of endocrine therapies.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). PMID 41633909 · Eur Urol Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial. PMID 41621679 · Radiother Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. PMID 41606119 · Nat Med · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Photodynamic Therapy Plus Topical Corticosteroid for Erosive Oral Lichen Planus: A Randomized Clinical Trial. PMID 41581340 · Int Dent J · 2026-Apr The study is a randomized controlled trial of a drug-containing intervention (photodynamic therapy combined with topical corticosteroid) with primary efficacy outcomes. However, it is excluded because it does not address a human malignant neoplasm (oral lichen planus is a non-malignant inflammatory condition) and lacks the required time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant therapy in skin cancer: current evidence and future perspectives. PMID 41580899 · J Dtsch Dermatol Ges · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized comparative study of 5-Fluorouracil 4%, tirbanibulin, and photodynamic therapy for relapsing actinic keratoses. PMID 41580230 · Photodiagnosis Photodyn Ther · 2026-Apr The study is a randomized, human, oncology trial with drug intervention and original results, but it lacks a primary or key secondary time-to-event efficacy endpoint as required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data. PMID 41580147 · Radiother Oncol · 2026-Apr The record reports secondary outcomes of a randomized trial. While it includes a time-to-event efficacy endpoint (PFS with HR), the abstract and metadata do not explicitly state the trial phase (e.g., Phase III/IIIb). The deterministic review correctly identifies 'phase3_evidence_unclear'. Since the required criterion of a definitive Phase III/IIIb or Phase II/III phase is not explicitly established in the provided text, eligibility cannot be confirmed. The report is also a secondary analysis, not the primary result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Test results and follow-up care stemming from an ED-based cervical cancer intervention. PMID 41579525 · Am J Emerg Med · 2026-Apr The study is a randomized trial of an ED-based cervical cancer screening intervention, not a drug intervention trial. It lacks the required Phase III/IIIb or Phase II/III drug trial structure and a primary time-to-event efficacy endpoint (like OS or PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study. PMID 41575731 · Rheumatol Ther · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The effect of structured patient-to-patient communication on fear of cancer recurrence in total laryngectomy patients: A randomized controlled trial. PMID 41564457 · Auris Nasus Larynx · 2026-Apr The record describes a randomized controlled trial evaluating a non-drug intervention (patient-to-patient communication) for fear of cancer recurrence in laryngeal cancer patients. It meets oncology, human, and randomized criteria. However, it lacks a drug intervention and a time-to-event efficacy endpoint (like OS, PFS, etc.), which are required for inclusion. The primary endpoints are fear of cancer recurrence (FCRI scores) and swallowing-related quality of life (SWAL-QOL), which are patient-reported outcomes, not survival or time-to-event measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -